Last reviewed · How we verify
Lorcaserin Dose #2
At a glance
| Generic name | Lorcaserin Dose #2 |
|---|---|
| Sponsor | Eisai Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (PHASE3)
- Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity (PHASE4)
- Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder (PHASE1)
- Evaluating Muscle Weakness Improvement With Lorcaserin in ICU (PHASE1, PHASE2)
- A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults (PHASE4)
- Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users (PHASE1)
- Combination Nicotine Patch / Lorcaserin for Smoking Cessation (PHASE2)
- A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |